Navigation Links
BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
Date:12/7/2010

NOVATO, Calif., Dec. 7, 2010 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will present a company update at the Deutsche Bank 2010 BioFEST Conference in Boston on Tuesday, December 14, 2010 at 9:00 a.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
2. BioMarin Announces Third Quarter 2010 Financial Results
3. BioMarin to Host a Research and Development Day on October 19th
4. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
5. BioMarin to Present at the UBS Global Life Sciences Conference
6. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
7. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
8. BioMarin Acquires ZyStor Therapeutics, Inc.
9. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)... 2013  BioRestorative Therapies, Inc. ("BRT" or the "Company") ... developing stem cell based therapies for various personal applications, ... President and CEO, will be presenting at the Marcum ... held on Thursday, May 30, 2013 at the Grand ... New York City.  Mr. Weinreb,s presentation will take place ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
... one of New Zealand,s leading hospitals have delivered more ... in the first month of its implementation. The TrueBeam ... ) adds to Wellington Hospital,s radiotherapy capabilities and enables ... first patient in the country – and the southern ...
Belgium, United Kingdom, Austria and The Netherlands. The DORC companies employ about 300 people. Visit our website : http://www.dorc.nl  ...
Cached Medicine Technology:Wellington Hospital, New Zealand Becomes First in Southern Hemisphere to Offer Patients Fast and Precise TrueBeam Treatments 2Wellington Hospital, New Zealand Becomes First in Southern Hemisphere to Offer Patients Fast and Precise TrueBeam Treatments 3
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- The risk of ... when parents sleep with their infant, a new study ... risk for SIDS even if parents do not drink, ... of SIDS, which is a major cause of infant ... did not sleep with their babies. In the ...
(Date:5/21/2013)... Brussels proposes to include on tobacco packages in order ... on smokers because they only find some of them ... improve the efficacy of its anti-smoking campaigns, it should ... stronger emotional impact., These are some of the conclusions ... and Psychological Treatment at the University of Granada by ...
(Date:5/21/2013)... have long been known for their health benefits, ... therapies like anti-cancer drugs are delivered to specific ... uncovered how to create nanoparticles using natural lipids ... use them as drug delivery vehicles. UofL scientists ... their team today (May 21, 2013), published their ...
(Date:5/21/2013)... Tulsa, OK (PRWEB) May 21, 2013 Representatives ... has been such a success that the company has achieved ... re-launch plan from day one was to move Hammerhead Bicycles ... Company Spokesman and President Scott Robertson. , Robertson explained that ... and continue to exclusively focus on all things 29er ...
(Date:5/21/2013)... 2013 TheBeautyPlace.com helps brides to breathe ... a Big Day Kit including all the essentials a ... shine on their Wedding Day. , TheBeautyPlace.com features Wedding ... on their Wedding Day. Flowers blooming and warmer weather ... wedding season. From Memorial Day to October, brides to ...
Breaking Medicine News(10 mins):Health News:Bed-Sharing Raises SIDS Risk Fivefold, Study Finds 2Health News:Warning images for cigarette packs proposed by Europe do not make enough emotional impact 2Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Hammerhead Bicycles Now a Standalone Brand 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 3
... is pondering, , TUESDAY, July 28 (HealthDay News) -- A ... raise the age at which American women should start Pap ... age at which a woman should first have a Pap ... States, however, women are told to get regular Pap smears ...
... , LAS VEGAS, July 28 American Pacific ... will release its Fiscal 2009 third quarter financial results on Tuesday, August 4, ... to participate in a teleconference to review the financial results and outlook of ... August 4, 2009 at 1:30 p.m. PDT. To access the call please dial ...
... , , DENVER, ... around the world were honored for research projects that improved ... projects were funded through Morris Animal Foundation,s (MAF) Veterinary Student ... annual meeting in June. Members of MAF,s esteemed scientific advisory ...
... , , , ... company that is expected to become public following the planned spinoff of ... 10 registration statement for the spinoff has been declared effective by the ... The effectiveness of the Form 10 was one of the few ...
... , , DETROIT, July 28 ... net sales of $48.1 million in the first quarter of Fiscal ... corresponding period of Fiscal 2009. The reduction in sales was primarily ... period, as compared to the corresponding period of Fiscal 2009. Sales ...
... , , CUPERTINO, Calif., July 28 ... Matthew Hogan, Chief Financial Officer, will be presenting at the BMO ... 5 at 4:00 pm Eastern Time. The conference is being ... A webcast of the presentation will be accessible at: ...
Cached Medicine News:Health News:Teens May Not Benefit from Pap Tests 2Health News:Teens May Not Benefit from Pap Tests 3Health News:American Pacific to Release Financial Results and Hold Fiscal 2009 Third Quarter Investor Teleconference 2Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 2Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 3Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 4Health News:CareFusion Form 10 Registration Statement Declared Effective 2Health News:CareFusion Form 10 Registration Statement Declared Effective 3Health News:CareFusion Form 10 Registration Statement Declared Effective 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 5Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 6Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010 7Health News:DURECT to Present at the BMO Capital Markets Healthcare Conference 2
Size: Medium. 22.50 mm by 24.00 mm. Clear lucite. Supplied sterile....
... 6.4 x 80 mm. Storz offers ... designed by Harvey A. Lincoff, M.D. ... cell sponge which is non-toxic and ... edges to minimize scleral intrusion. These ...
... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. The ... which is non-toxic and non-antigenic. Implants ... minimize scleral intrusion. These implants are ...
... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
Medicine Products: